Cargando…
Incidence and prevalence of lupus in Buenos Aires, Argentina: a 11-year health management organisation-based study
OBJECTIVES: Studies regarding the epidemiology of systemic lupus erythematosus (SLE) are lacking in Argentina. Our purpose was to estimate the incidence and prevalence of SLE in a university hospital-based health management organisation in Buenos Aires (HIMCP). METHODS: For incidence calculation, th...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4213830/ https://www.ncbi.nlm.nih.gov/pubmed/25379189 http://dx.doi.org/10.1136/lupus-2014-000021 |
_version_ | 1782341874428674048 |
---|---|
author | Scolnik, M Marin, J Valeiras, S M Marchese, M F Talani, A S Avellaneda, N L Etchepare, A Etchepare, P Plou, M S Soriano, E R |
author_facet | Scolnik, M Marin, J Valeiras, S M Marchese, M F Talani, A S Avellaneda, N L Etchepare, A Etchepare, P Plou, M S Soriano, E R |
author_sort | Scolnik, M |
collection | PubMed |
description | OBJECTIVES: Studies regarding the epidemiology of systemic lupus erythematosus (SLE) are lacking in Argentina. Our purpose was to estimate the incidence and prevalence of SLE in a university hospital-based health management organisation in Buenos Aires (HIMCP). METHODS: For incidence calculation, the population at risk included all adult members of the HIMCP, with continuous affiliation for at least 1 year from January 1998 to January 2009. Each person was followed until he/she voluntarily left the HIMCP, death or finalisation of the study. Multiple methods for case finding were used to ensure complete ascertainment: (a) patients with problem SLE, undifferentiated autoimmune disease or mixed connective tissue disease in the Computer-based Patient Record System, (b) patients with positive antinuclear antibody test, anti-Sm antibodies and/or anti-dsDNA antibodies in the laboratory database and (c) patients who consumed hydroxichloroquine, chloroquine, azathioprine, cyclophosphamide, mycophenolate, cyclosporine or rituximab, from the administrative HIMCP drugs database. Medical records of all patients found were reviewed, and only patients fulfilling ACR criteria for SLE were included. Global and gender incidence rate (IR) was calculated. Prevalence was estimated on 1 January 2009, and the denominator population was the number of active members >18 years at that date (n=127 959). RESULTS: In the study period, 68 patients developed SLE. The observed IR (per 100 000 person-years, (CI 95%)) was 6.3 (4.9 to 7.7) for total population; 8.9 (CI 6.6 to 11.2) for women and 2.6 (1.2 to 3.9) for men. On 1 January 2009, 75 prevalent cases were identified. Prevalence rates (cases per 100 000 habitants, (CI 95%)) were 58.6 (46.1 to 73.5) for total population; 83.2 (63.9 to 106.4) for women and 23 (CI 11.9 to 40.1) for men. CONCLUSIONS: SLE incidence and prevalence rates in Argentina are in agreement with those of other studies from different parts of the world. |
format | Online Article Text |
id | pubmed-4213830 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-42138302014-11-06 Incidence and prevalence of lupus in Buenos Aires, Argentina: a 11-year health management organisation-based study Scolnik, M Marin, J Valeiras, S M Marchese, M F Talani, A S Avellaneda, N L Etchepare, A Etchepare, P Plou, M S Soriano, E R Lupus Sci Med Epidemiology and Outcomes OBJECTIVES: Studies regarding the epidemiology of systemic lupus erythematosus (SLE) are lacking in Argentina. Our purpose was to estimate the incidence and prevalence of SLE in a university hospital-based health management organisation in Buenos Aires (HIMCP). METHODS: For incidence calculation, the population at risk included all adult members of the HIMCP, with continuous affiliation for at least 1 year from January 1998 to January 2009. Each person was followed until he/she voluntarily left the HIMCP, death or finalisation of the study. Multiple methods for case finding were used to ensure complete ascertainment: (a) patients with problem SLE, undifferentiated autoimmune disease or mixed connective tissue disease in the Computer-based Patient Record System, (b) patients with positive antinuclear antibody test, anti-Sm antibodies and/or anti-dsDNA antibodies in the laboratory database and (c) patients who consumed hydroxichloroquine, chloroquine, azathioprine, cyclophosphamide, mycophenolate, cyclosporine or rituximab, from the administrative HIMCP drugs database. Medical records of all patients found were reviewed, and only patients fulfilling ACR criteria for SLE were included. Global and gender incidence rate (IR) was calculated. Prevalence was estimated on 1 January 2009, and the denominator population was the number of active members >18 years at that date (n=127 959). RESULTS: In the study period, 68 patients developed SLE. The observed IR (per 100 000 person-years, (CI 95%)) was 6.3 (4.9 to 7.7) for total population; 8.9 (CI 6.6 to 11.2) for women and 2.6 (1.2 to 3.9) for men. On 1 January 2009, 75 prevalent cases were identified. Prevalence rates (cases per 100 000 habitants, (CI 95%)) were 58.6 (46.1 to 73.5) for total population; 83.2 (63.9 to 106.4) for women and 23 (CI 11.9 to 40.1) for men. CONCLUSIONS: SLE incidence and prevalence rates in Argentina are in agreement with those of other studies from different parts of the world. BMJ Publishing Group 2014-06-05 /pmc/articles/PMC4213830/ /pubmed/25379189 http://dx.doi.org/10.1136/lupus-2014-000021 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/ |
spellingShingle | Epidemiology and Outcomes Scolnik, M Marin, J Valeiras, S M Marchese, M F Talani, A S Avellaneda, N L Etchepare, A Etchepare, P Plou, M S Soriano, E R Incidence and prevalence of lupus in Buenos Aires, Argentina: a 11-year health management organisation-based study |
title | Incidence and prevalence of lupus in Buenos Aires, Argentina: a 11-year health management organisation-based study |
title_full | Incidence and prevalence of lupus in Buenos Aires, Argentina: a 11-year health management organisation-based study |
title_fullStr | Incidence and prevalence of lupus in Buenos Aires, Argentina: a 11-year health management organisation-based study |
title_full_unstemmed | Incidence and prevalence of lupus in Buenos Aires, Argentina: a 11-year health management organisation-based study |
title_short | Incidence and prevalence of lupus in Buenos Aires, Argentina: a 11-year health management organisation-based study |
title_sort | incidence and prevalence of lupus in buenos aires, argentina: a 11-year health management organisation-based study |
topic | Epidemiology and Outcomes |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4213830/ https://www.ncbi.nlm.nih.gov/pubmed/25379189 http://dx.doi.org/10.1136/lupus-2014-000021 |
work_keys_str_mv | AT scolnikm incidenceandprevalenceoflupusinbuenosairesargentinaa11yearhealthmanagementorganisationbasedstudy AT marinj incidenceandprevalenceoflupusinbuenosairesargentinaa11yearhealthmanagementorganisationbasedstudy AT valeirassm incidenceandprevalenceoflupusinbuenosairesargentinaa11yearhealthmanagementorganisationbasedstudy AT marchesemf incidenceandprevalenceoflupusinbuenosairesargentinaa11yearhealthmanagementorganisationbasedstudy AT talanias incidenceandprevalenceoflupusinbuenosairesargentinaa11yearhealthmanagementorganisationbasedstudy AT avellanedanl incidenceandprevalenceoflupusinbuenosairesargentinaa11yearhealthmanagementorganisationbasedstudy AT etcheparea incidenceandprevalenceoflupusinbuenosairesargentinaa11yearhealthmanagementorganisationbasedstudy AT etcheparep incidenceandprevalenceoflupusinbuenosairesargentinaa11yearhealthmanagementorganisationbasedstudy AT ploums incidenceandprevalenceoflupusinbuenosairesargentinaa11yearhealthmanagementorganisationbasedstudy AT sorianoer incidenceandprevalenceoflupusinbuenosairesargentinaa11yearhealthmanagementorganisationbasedstudy |